Quality of life and depression in Parkinson's disease

Journal of the Neurological Sciences

Volumn 248, Issue 1-2, 2006, Pages 151-157

  Schrag, Anette ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Depression; Health related quality of life; Parkinson's disease; Review

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; PRAMIPEXOLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; COMORBIDITY; CORRELATION ANALYSIS; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GERIATRIC DEPRESSION SCALE; HAMILTON SCALE; HUMAN; LITERATURE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SOCIAL STATUS; SYMPTOM;

DEPRESSION; HUMANS; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 33750483618     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.05.030     Document Type: Article

References (88)

1. Spilker B., and Revicki D.A. Taxonomy of quality of life. In: Spilker B. (Ed). Quality of life and pharmacoeconomics in clinical trials (1996), Lippincott-Raven Publishers, Philadelphia
2. Streiner D.L., and Norman G.R. Health measurement scales: a practical guide to their development and use. 2 ed. (1995), OUP, Oxford
3. Hunt S.M., McEwen J., and McKenna S.P. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 35 273 (1985) 185-188
4. Bergner M., Bobbitt R.A., Carter W.B., and Gilson B.S. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 19 8 (1981) 787-805
5. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 30 6 (1992) 473-483
6. Haapaniemi T.H., Sotaniemi K.A., Sintonen H., and Taimela E. The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson's disease. J Neurol Neurosurg Psychiatry 75 7 (2004) 976-983
7. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16 3 (1990) 199-208
8. Siderowf A., Ravina B., and Glick H.A. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 59 1 (2002) 103-108
9. Marinus J., Ramaker C., van Hilten J.J., and Stiggelbout A.M. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J Neurol Neurosurg Psychiatry 72 2 (2002) 241-248
10. Marinus J., Visser M., Martinez-Martin P., van Hilten J.J., and Stiggelbout A.M. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 56 1 (2003) 61-67
11. Spliethoff-Kamminga N.G., Zwinderman A.H., Springer M.P., and Roos R.A. Psychosocial problems in Parkinson's disease: evaluation of a disease-specific questionnaire. Mov Disord 18 5 (2003) 503-509
12. Kuehler A., Henrich G., Schroeder U., Conrad B., Herschbach P., and Ceballos-Baumann A. A novel quality of life instrument for deep brain stimulation in movement disorders. J Neurol Neurosurg Psychiatry 74 8 (2003) 1023-1030
13. Moore O., Gurevich T., Korczyn A.D., Anca M., Shabtai H., and Giladi N. Quality of sexual life in Parkinson's disease. Parkinsonism Relat Disord 8 4 (2002) 243-246
14. Karlsen K.H., Larsen J.P., Tandberg E., and Maland J.G. Quality of life measurements in patients with Parkinson's disease: a community-based study. Eur J Neurol 5 5 (1998) 443-450
15. Damiano A.M., McGrath M.M., Willian M.K., Snyder C.F., LeWitt P.A., Reyes P.F., et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 9 1 (2000) 87-100
16. Schrag A., Jahanshahi M., and Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15 6 (2000) 1112-1118
17. Kuopio A.M., Marttila R.J., Helenius H., Toivonen M., and Rinne U.K. The quality of life in Parkinson's disease. Mov Disord 15 2 (2000) 216-223
18. Fitzpatrick R., Peto V., Jenkinson C., Greenhall R., and Hyman N. Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord 12 6 (1997) 916-922
19. Martinez-Martin P., Frades P.B., Fontan T.C., Martinez Sarries F.J., Guerrero M.T., and del Ser Q.T. Assessing quality of life in Parkinson's disease using the PDQ-39. A pilot study. Neurologia 12 2 (1997) 56-60
20. Harrison J.E., Preston S., and Blunt S.B. Measuring symptom change in patients with Parkinson's disease. Age Ageing 29 1 (2000) 41-45
21. Chapuis S., Ouchchane L., Metz O., Gerbaud L., and Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 20 2 (2005) 224-230
22. Schrag A., Jahanshahi M., and Quinn N. What contributes to quality of life in patients with Parkinson's disease?. J Neurol Neurosurg Psychiatry 69 3 (2000) 308-312
23. Lyons K.E., Pahwa R., Troester A.E., and Koller W.C. A comparison of Parkinson's disease symptoms and self-reported functioning and well being. Parkinsonism Relat Disord 3 (1998) 207-209
24. GPDSC. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17 1 (2002) 60-67
25. Rubenstein L.M., Voelker M.D., Chrischilles E.A., Glenn D.C., Wallace R.B., and Rodnitzky R.L. The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research. Qual Life Res 7 4 (1998) 279-290
26. Calne S.M., Mak E., Hall J., Fortin M.J., King P., McInnes G., et al. Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Adv Neurol 91 (2003) 115-122
27. Lyons K.E., Pahwa R., and Troester A.E. A comparison of Parkinson's disease symptoms and self-reported functioning and well being. Parkinsonism Relat Disord 3 (1998) 207-209
28. Karlsen K.H., Larsen J.P., Tandberg E., and Maeland J.G. Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 66 4 (1999) 431-435
29. Hobson P., Holden A., and Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing 28 4 (1999) 341-346
30. Caap-Ahlgren M., and Dehlin O. Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 32 1 (2001) 23-33
31. Zach M., Friedman A., Slawek J., and Derejko M. Quality of life in Polish patients with long-lasting Parkinson's disease. Mov Disord 19 6 (2004) 667-672
32. Schrag A., Hovris A., Morley D., Quinn N., and Jahanshahi M. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 18 11 (2003) 1250-1256
33. Kostic V.S., Filipovic S.R., Lecic D., Momcilovic D., Sokic D., and Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 57 10 (1994) 1265-1267
34. Marras C., Lang A., Krahn M., Tomlinson G., and Naglie G. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. Mov Disord 19 1 (2004) 22-28
35. Menza M.A., Sage J., Marshall E., Cody R., and Duvoisin R. Mood changes and "on-off" phenomena in Parkinson's disease. Mov Disord 5 2 (1990) 148-151
36. Nissenbaum H., Quinn N.P., Brown R.G., Toone B., Gotham A.M., and Marsden C.D. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 17 4 (1987) 899-904
37. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th, Text Revision (DS-IV-TR) ed. D. Washington, C.: American Psychiatric Association, 2000.
38. M.B. First, R.L. Spitzer, M. Gibbon, J.B.W. Wiliams, Structured clinical interview for DSM-IV Axis I disorders. Patient Edition ed. New York: 1995.
39. Wing J.K., Babor T., Brugha T., Burke J., Cooper J.E., Giel R., et al. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 47 6 (1990) 589-593
40. Marsh L., McDonald W.M., Cummings J., and Ravina B. NINDS/NIMH Work Group on Depression and Parkinson's Disease. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 21 (2006) 148-158
41. Starkstein S.E., Preziosi T.J., Bolduc P.L., and Robinson R.G. Depression in Parkinson's disease. J Nerv Ment Dis 178 1 (1990) 27-31
42. Meara J., Mitchelmore E., and Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 28 1 (1999) 35-38
43. Schrag A., Jahanshahi M., and Quinn N.P. What contributes to depression in Parkinson's disease?. Psychol Med 31 1 (2001) 65-73
44. Tandberg E., Larsen J.P., Aarsland D., and Cummings J.L. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 53 2 (1996) 175-179
45. Zung W.W.K. A self-rating depression scale. Arch Gen Psychiatry 12 (1965) 63-70
46. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 6 (1983) 361-370
47. Dooneief G., Mirabello E., Bell K., Marder K., Stern Y., and Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 49 3 (1992) 305-307
48. Schrag A., Hovris A., Morley D., Quinn N., and Jahanshahi M. Young-versus older-onset Parkinson's disease: impact of disease and psychosocial consequences. Mov Disord 18 11 (2003) 1250-1256
49. Brown R., and Jahanshahi M. Depression in Parkinson's disease: a psychosocial viewpoint. Adv Neurol 65 (1995) 61-84
50. Rojo A., Aguilar M., Garolera M.T., Cubo E., Navas I., and Quintana S. Depression in Parkinson's disease: clinical correlates and outcome. Parkinsonism Relat Disord 10 1 (2003) 23-28
51. Schrag A., Hovris A., Morley D., Quinn N., and Jahanshahi M. Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 12 1 (2006) 35-41
52. Weintraub D., Moberg P.J., Duda J.E., Katz I.R., and Stern M.B. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 52 5 (2004) 784-788
53. Marder K., Tang M.X., Cote L., Stern Y., and Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 52 7 (1995) 695-701
54. Starkstein S.E., Mayberg H.S., Leiguarda R., Preziosi T.J., and Robinson R.G. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 55 5 (1992) 377-382
55. Stern Y., Marder K., Tang M.X., and Mayeux R. Antecedent clinical features associated with dementia in Parkinson's disease. Neurology 43 9 (1993) 1690-1692
56. Gotham A.M., Brown R.G., and Marsden C.D. Depression in Parkinson's disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49 4 (1986) 381-389
57. Nilsson F.M., Kessing L.V., Sorensen T.M., Andersen P.K., and Bolwig T.G. Major depressive disorder in Parkinson's disease: a register-based study. Acta Psychiatr Scand 106 3 (2002) 202-211
58. Shiba M., Bower J.H., Maraganore D.M., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15 4 (2000) 669-677
59. Menza M.A., Palermo B., DiPaola R., Sage J.I., and Ricketts M.H. Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. J Geriatr Psychiatry Neurol 12 2 (1999) 49-52
60. Mossner R., Henneberg A., Schmitt A., Syagailo Y.V., Grassle M., Hennig T., et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry 6 3 (2001) 350-352
61. Mayeux R., Stern Y., Cote L., and Williams J.B. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34 5 (1984) 642-646
62. Mayeux R., Stern Y., Sano M., Williams J.B., and Cote L.J. The relationship of serotonin to depression in Parkinson's disease. Mov Disord 3 3 (1988) 237-244
63. Kostic V.S., Djuricic B.M., Covickovic-Sternic N., Bumbasirevic L., Nikolic M., and Mrsulja B.B. Depression and Parkinson's disease: possible role of serotonergic mechanisms. J Neurol 234 2 (1987) 94-96
64. Chan-Palay V. Depression and dementia in Parkinson's disease. Catecholamine changes in the locus ceruleus, a basis for therapy. Adv Neurol 60 (1993) 438-446
65. Doder M., Rabiner E.A., Turjanski N., Lees A.J., and Brooks D.J. Brain serotonin IA receptors in Parkinson's disease with and without depression measured by positron emission tomography with 11C-WAY 10635. Mov Disord 15 (2000) 213 [Abstract]
66. Remy P., Doder M., Lees A., Turjanski N., and Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 Pt 6 (2005) 1314-1322
67. Weintraub D., Newberg A.B., Cary M.S., Siderowf A.D., Moberg P.J., Kleiner-Fisman G., et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 46 2 (2005) 227-232
68. Menza M., Marin H., Kaufman K., Mark M., and Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 16 3 (2004) 315-319
69. Shabnam G.N., Chung T.H., Deane K.H.O., Rickards H., and Clarke C.E. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 3 (2003) [CD003465]
70. Ceravolo R., Nuti A., Piccinni A., Dell'Agnello G., Bellini G., Gambaccini G., et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 55 8 (2000) 1216-1218
71. Tesei S., Antonini A., Canesi M., Zecchinelli A., Mariani C.B., and Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 15 5 (2000) 986-989
72. Lemke M.R. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 63 4 (2002) 300-304
73. Takahashi H., Kamata M., Yoshida K., Higuchi H., and Shimizu T. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports. Prog Neuropsychopharmacol Biol Psychiatry 29 2 (2005) 351-353
74. Moller J.C., Oertel W.H., Koster J., Pezzoli G., and Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European Multicenter Trial. Mov Disord 20 5 (2005) 602-610
75. Reichmann H., Brecht M.H., Koster J., Kraus P.H., and Lemke M.R. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs 17 13 (2003) 965-973
76. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., and Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 11 2 (2000) 58-65
77. Gerstenbrand F., Ransmayr G., and Poewe W. Deprenyl (selegiline) in combination treatment of Parkinson's disease. Acta Neurol Scand Suppl 95 (1983) 123-126
78. Allain H., Pollak P., and Neukirch H.C. Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial. Mov Disord 8 Suppl 1 (1993) S36-S40
79. Weintraub D., Moberg P.J., Duda J.E., Katz I.R., and Stern M.B. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 16 3 (2003) 178-183
80. Trivedi M.H., Pigotti T.A., Perera P., Dillingham K.E., Carfagno M.L., and Pitts C.D. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry 65 10 (2004) 1356-1364
81. Troster A.I., Fields J.A., Wilkinson S., Pahwa R., Koller W.C., and Lyons K.E. Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. Stereotact Funct Neurosurg 80 1-4 (2003) 43-47
82. Gomez J.C., Lezcano E., Molano A., Lambarri I., Bilbao G., Garibi J., et al. Neuropsychological changes and bilateral subthalamic deep brain stimulation in Parkinson's disease. Neurologia 18 3 (2003) 139-145
83. Peto V., Jenkinson C., and Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 245 Suppl 1 (1998) S10-S14
84. Jenkinson C., Peto V., Fitzpatrick R., Greenhall R., and Hyman N. Self-reported functioning and well-being in patients with Parkinson's disease: comparison of the Short-Form Health Survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing 24 6 (1995) 505-509
85. de Boer A.G., Wijker W., Speelman J.D., and de Haes J.C. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 61 1 (1996) 70-74
86. Welsh M., McDermott M.P., Holloway R.G., Plumb S., Pfeiffer R., and Hubble J. Development and testing of the Parkinson's disease quality of life scale. Mov Disord 18 6 (2003) 637-645
87. Hogan T., Grimaldi R., Dingemanse J., Martin M., Lyons K., and Koller W. The Parkinson's disease symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects. Parkinsonism Relat Disord 5 (1999) 93-98
88. Karlsen K.H., Tandberg E., Arsland D., and Larsen J.P. Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 69 5 (2000) 584-589